1ST Biotherapeutics Revenue

Biotechnology Research • • 1-10 Employees

1ST Biotherapeutics revenue & valuation

Annual revenue	$342,220
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$1,100,000
Total funding	No funding

Key Contact at 1ST Biotherapeutics

Yehwan Chang

Director

Company overview

Headquarters	XX
Website	1stbio.com
NAICS	541714
Employees	1-10

About 1ST Biotherapeutics

• Founded in May 2016 near Seoul, South Korea, 1STBIO is focused on developing breakthrough medicines to address the highest unmet needs in oncology and neurology • 3 clinical stage programs - HPK1 inhibitor (I-O): Phase 1/2 in US - c-Abl inhibitor (neuro): Phase 1 in US and Korea - c-Abl PET tracer for c-Abl patient selection: Entering Phase 1 in EU • Experienced leadership team with a proven business and R&D track record • Small molecule discovery engine that has successfully created highly differentiated drug candidates

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Funding Data

1ST Biotherapeutics has never raised funding before.

Frequently asked questions

1ST Biotherapeutics is located in XX.

1ST Biotherapeutics generates an estimated annual revenue of $342,220. This revenue figure reflects the company's market position and business performance in its industry.

1ST Biotherapeutics has an estimated valuation of $1,100,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

1ST Biotherapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at 1ST Biotherapeutics

Yehwan Chang

Director

4.8

40,000 users